<!DOCTYPE html>
<html lang="en">
<head id="Head1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <meta http-equiv="content-type" content="text/html;charset=utf-8" />
    <meta http-equiv="X-UA-Compatible" content="IE=Edge" />
    <meta charset="utf-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <title>Full Text of HB1102</title>
    <link rel="shortcut icon" type="image/x-icon" href="https://cdn.ilga.gov/assets/img/site/favicon.ico" />
    <link rel="stylesheet" href="https://cdn.ilga.gov/assets/css/bootstrap/bootstrap-4.6.2-dist/css/bootstrap.min.css" />
    <link href="https://cdnjs.cloudflare.com/ajax/libs/bootstrap-table/1.18.3/bootstrap-table.min.css" rel="stylesheet">
    <link href="https://cdnjs.cloudflare.com/ajax/libs/bootstrap-table/1.18.3/extensions/filter-control/bootstrap-table-filter-control.min.css" rel="stylesheet">
    <link href="https://cdnjs.cloudflare.com/ajax/libs/bootstrap-table/1.18.3/extensions/filter-control/bootstrap-table-filter-control.min.css" rel="stylesheet">
    <script src="https://cdn.ilga.gov/assets/js/fontawesome/fa.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/jquery/jquery.min.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/jquery/js.cookie.min.js"></script>
    <script async src="https://cse.google.com/cse.js?cx=a47f92b5e11c1499a"></script> 
    <!-- Bootstrap Datepicker CSS -->
    <link rel="stylesheet" href="https://cdn.ilga.gov/assets/css/bootstrap/bootstrap-4.6.2-dist/css/bootstrap-datepicker.min.css">
    <!-- Bootstrap Datepicker JavaScript -->
    <script src="https://cdn.ilga.gov/assets/js/bootstrap/bootstrap-datepicker.min.js"></script>
    <!-- aos, bootstrap icons, swiper CSS -->
    <link href="https://cdn.ilga.gov/assets/css/aos/aos.css" rel="stylesheet">
    <link href="https://cdn.ilga.gov/assets/css/swiper/swiper-bundle.min.css" rel="stylesheet">

    <script src="https://cdnjs.cloudflare.com/ajax/libs/bootstrap-table/1.18.3/bootstrap-table.min.js"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/bootstrap-table/1.18.3/extensions/filter-control/bootstrap-table-filter-control.min.js"></script>

    <!-- ILGA main CSS -->
    <link rel="stylesheet" href="https://cdn.ilga.gov/main.css" />
    <link rel="stylesheet" type="text/css" media="print" href="https://cdn.ilga.gov/assets/css/print.css">
    <style></style>
    
</head>
<body>
        <!-- ======= Header ======= -->
        <header id="print-header" class="d-flex align-items-center">
            <div class="container-fluid align-items-center text-uppercase justify-content-start ">
                <div class="logo ">
                    <a href="/"><img src="https://cdn.ilga.gov/assets/img/site/white_capitol.png" alt="ILGA Logo"><span>ILGA.GOV</span></a>
                </div>
                <div class="w-100"></div>
            </div>
        </header>
    <input id="TextSearch" type="hidden" />
    <input id="MobileTextSearch" type="hidden" />
    <input id="message-input" type="hidden" />

    <main id="main-content" role="main">
        <section class="main-page p-2">
	<div class="p-1 pt-4 float-left">
		<div class="row border-bottom pb-3 mb-3">
			<div class="text-start">
				<h2>
					HB1102 - 104th General Assembly
				</h2><br />
			</div>
		</div>
		<div id="content">
			<!-- Full text only shows on large screens -->
			<div class="centered-container d-lg-flex">
				<div class="left-aligned-content">
					<div class="row">
						<div class="col pl-lg-5" translate="no">
							<text class="ml-5 text-left fulltextLineHeight" id="billtextanchor">
								<style>
								
								
								
								table.xsl	{ 	border-collapse: collapse;
												border: 0px solid black;
												font-family: "courier New"; 
												font-size: 10pt;}
								
								td.xsl		{ 	border-collapse: collapse;
												border: 0px solid black;
												padding-top: 3pt;
												padding-bottom: 3pt;
												padding-left: 0pt;
												padding-right: 0pt;
												font-family: "courier New"; 
												font-size: 10pt; }
												
								td.junk		{ 	width: 5%; }
								 
							
					
					
						body.xsl		{ 	text-align:center; }
						
					
						td.lineNum 		{ 	vertical-align: top; 
										  	text-align: right;
										  	font-family: "courier New"; 
										  	font-size: 10pt; }
							
						td.number 		{	width: 5%;
											vertical-align: top; 
										  	text-align: right;
										  	font-family: "Courier New", sans-serif;
										  	font-size: 10pt; }
						
						td.synopsis		{ 	border-collapse: collapse;
											border: 0px solid black;
											padding-top: 0pt;
											padding-bottom: 0pt;
											padding-left: 0pt;
											padding-right: 0pt;
											font-family: "courier New"; 
											font-size: 10pt; }
						
						td.rowsep		{ 	border-bottom: 1px solid black; }
											
						td.colsep		{ 	border-right: 1px solid black; }
											
						td.bothsep		{ 	border-right: 1px solid black;
										  	border-bottom: 1px solid black; }
	
						table.top		{ 	font-family: "Courier New", sans-serif;
									  	  	font-size: 10pt;
									  	  	border-top: 1px solid black; }
											
						table.bottom	{ 	font-family: "Courier New", sans-serif;
									  	  	font-size: 10pt;
									  	  	border-bottom: 1px solid black; }
											
						table.sides		{ 	font-family: "Courier New", sans-serif;
									  	  	font-size: 10pt;
									  	  	border-left: 1px solid black;
									  	  	border-right: 1px solid black; }
	
						table.all		{ 	font-family: "Courier New", sans-serif;
										  	font-size: 10pt;
									  	  	border-left: 1px solid black;
									  	  	border-right: 1px solid black;
									  	  	border-bottom: 1px solid black;
									  	  	border-top: 1px solid black; }				
	
						table.topbot	{ 	border-collapse: separate;
									  	  	border: outset 0pt;
										  	font-family: "Courier New", sans-serif;
									  	  	font-size: 10pt;
									  	  	border-top: 1px solid black;
									  	  	border-bottom: 1px solid black; }
					
						.sigline		{ 	text-align: left;
							 		 		vertical-align: bottom;
							 				padding-top: 3pt;
							 				padding: 0pt; }
							 				
						.siglinetext		{ 	text-align: left;
							 		 		vertical-align: top;
							 				padding-top: 3pt;
							 				padding: 0pt; }
							 				
						.sigtitle		{ 	text-align: left;
							 				vertical-align: top;
							 				padding: 0pt; }
							 				  
						.sigtitlenum		{ 	text-align: right;
							 				vertical-align: top;
							 				padding: 0pt; }
							
						.siglinenum		{ 	text-align: right;
							 				vertical-align: center;
							 				padding-top: 3pt;
							 				padding: 0pt; }
					</style><table class="xsl" width="578"><pre><tr><td class="xsl" colspan="3"><p> </p><br> </td></tr></td></tr><tr><td class="number"></td><td class="junk"></td><td class="xsl"><table class="xsl" width="100%"><tr><td class="xsl"><center><b><pre><font size="3" face="Courier New">104TH GENERAL ASSEMBLY
State of Illinois
2025 and 2026</font><br>HB1102</pre></b></center><p> </p>Introduced 1/9/2025, by Rep. Jed Davis<p> </p><b>SYNOPSIS AS INTRODUCED:</b><br> </td></tr><tr><td class="xsl"></td></tr><tr><td class="xsl"><table class="xsl" width="100%"><colgroup width="50%"></colgroup><colgroup width="50%"></colgroup><tr><td class="synopsis"><code>215 ILCS 5/356u</code></td><td class="synopsis"></td></tr></table><p></p></td></tr><tr><td class="xsl"><code>    </code><code>Amends the Illinois Insurance Code. In a provision concerning </code><code>coverage of certain cancer screenings, adds having a high level of CA-125, </code><code>as indicated by a blood test screening, to the definition of "at risk for </code><code>ovarian cancer". Provides that "surveillance tests for ovarian cancer" </code><code>means all medically viable methods for the detection and diagnosis of </code><code>ovarian cancer, including, but not limited to, ultrasounds, magnetic </code><code>resonance imagings (MRIs), x-rays, computed tomography (CT) scans, and </code><code>CA-125 blood test screenings (instead of an annual screening using (i) </code><code>CA-125 serum tumor marker testing, (ii) transvaginal ultrasound, (iii) </code><code>pelvic examination). Effective January 1, 2027.</code></td></tr><tr align="right" class="lineNum"><td class="xsl"><br><br></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left"></td><td class="xsl" align="center"></td><td class="xsl" align="right">LRB104 03831 BAB 13855 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="xsl"></td></tr><tr><td class="xsl"><p> </p><p> </p><center><b>A BILL FOR</b></center><p></p></td></tr></table><p> </p></td></tr><tr><td class="xsl"></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB1102</td><td class="xsl" align="center"></td><td class="xsl" align="right">LRB104 03831 BAB 13855 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>AN ACT concerning regulation.</code><br> </td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><b><code>Be it enacted by the People of the State of Illinois, </code></b></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><b><code>represented in the General Assembly:</code></b><br> </td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Section 5. </code><code>The Illinois Insurance Code is amended by </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>changing Section 356u as follows:</code><br> </td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(215 ILCS 5/356u)</code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Sec. 356u. </code><code>Pap tests and prostate cancer screenings. </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(a) A group policy of accident and health insurance that </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>provides coverage for hospital or medical treatment or </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>services for illness on an expense-incurred basis and is </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>amended, delivered, issued, or renewed after January 1, 2024 </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>shall provide coverage, without imposing a deductible, </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>coinsurance, copayment, or any other cost-sharing requirement, </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>for all of the following:</code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) An annual cervical smear or Pap smear test for all </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" >    <code>insureds.</code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) An annual prostate cancer screening for insureds </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" >    <code>upon the recommendation of a physician licensed to </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" >    <code>practice medicine in all its branches for:</code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(A) asymptomatic individuals age 50 and over;</code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(B) African-American individuals age 40 and over; </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" >        <code>and</code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(C) individuals age 40 and over with a family </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB1102</td><td class="xsl" align="center">- 2 -</td><td class="xsl" align="right">LRB104 03831 BAB 13855 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" >        <code>history of or genetic predisposition to prostate </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" >        <code>cancer.</code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) Surveillance tests for ovarian cancer for insureds </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" >    <code>who are at risk for ovarian cancer.</code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(b) This Section shall not apply to agreements, contracts, </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>or policies that provide coverage for a specified disease or </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>other limited benefit coverage.</code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(c) This Section does not apply to coverage of prostate </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>cancer screenings to the extent such coverage would disqualify </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>a high-deductible health plan from eligibility for a health </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>savings account pursuant to Section 223 of the Internal </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>Revenue Code. </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(d) For the purposes of this Section:</code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>"At risk for ovarian cancer" means:</code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) having a family history (i) with one or more </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" >    <code>first-degree relatives with ovarian cancer, (ii) of </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" >    <code>clusters of relatives with breast cancer, or (iii) of </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" >    <code>nonpolyposis colorectal cancer; </code><strike><code>or</code></strike></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) testing positive for BRCA1 or BRCA2 mutations</code><u><code>; or</code></u> <strike><code>.</code></strike></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><u><code>(3) having a high level of CA-125, as indicated by a </code></u></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" >    <u><code>blood test screening.</code></u><code> </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>"Prostate cancer screening" means medically viable methods </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>for the detection and diagnosis of prostate cancer, including </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>a digital rectal exam and the prostate-specific antigen test </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>and associated laboratory work. "Prostate cancer screening" </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>includes medically necessary subsequent follow-up testing as </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB1102</td><td class="xsl" align="center">- 3 -</td><td class="xsl" align="right">LRB104 03831 BAB 13855 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>directed by a health care provider, including, but not limited </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>to:</code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) urinary analysis;</code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) serum biomarkers; and</code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) medical imaging, including, but not limited to, </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" >    <code>magnetic resonance imaging. </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>"Surveillance tests for ovarian cancer" means </code><u><code>all </code></u></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><u><code>medically viable methods for the detection and diagnosis of </code></u></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><u><code>ovarian cancer, including, but not limited to, ultrasounds, </code></u></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><u><code>magnetic resonance imagings (MRIs), x-rays, computed </code></u></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><u><code>tomography (CT) scans, and CA-125 blood test screenings.</code></u><code> </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><strike><code>annual screening using (i) CA-125 serum tumor marker testing, </code></strike></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><strike><code>(ii) transvaginal ultrasound, (iii) pelvic examination.</code></strike><code> </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>(Source: P.A. 102-1073, eff. 1-1-23; 103-30, eff. 1-1-25</code><code>.)</code><br> </td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Section 99. </code><code>Effective date. </code><code>This Act takes effect January </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>1, 2027.</code></pre></table>
							</text>
						</div>
					</div>
				</div>
			</div>
		</div>
    </div>
</section>
    </main>
    <!-- Vendor JS Files -->
    <script src="https://cdn.ilga.gov/assets/js/aos/aos.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/jquery/popper.min.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/bootstrap/bootstrap.bundle.min.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/glightbox/glightbox.min.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/swiper/swiper-bundle.min.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/main.js"></script>

    

</body>
</html>
